Y-mabs announces regulatory filing for danyelza® (naxitamab-gqgk) in brazil

New york, sept. 26, 2022 (globe newswire) -- y-mabs therapeutics, inc. (“y-mabs”, nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that adium pharma s.a. (“adium”) has submitted a regulatory filing for danyelza® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the brazilian health regulatory agency, agÊncia nacional de vigilÂncia sanitÁria (“anvisa”).
YMAB Ratings Summary
YMAB Quant Ranking